Search research articles
Contact Us
Filters
Showing results (91-100 of 123) with videos related to
Page
of 13
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 30, 2000
A quality network model for the daily care of multiple sclerosis
L D Blumhardt, B J Vermeij, M Amato, et al.
Neurology
|
May 20, 1999
Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group
D Brassat, C Azais-Vuillemin, J Yaouanq, et al.
Genes and Immunity
|
October 11, 2003
Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis
I Cournu-Rebeix, E Génin, G Lesca, et al.
Lancet (London, England)
|
May 30, 2001
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
G Comi, M Filippi, F Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 3, 2002
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis
R G Ghalie, E Mauch, G Edan, et al.
Journal of Neurology
|
April 12, 2006
Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?
D Drapier, S Drapier, P Sauleau, et al.
Journal of Neuroimmunology
|
May 15, 2010
Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response
J Kovalchin, J Krieger, M Genova, et al.
European Journal of Neurology
|
February 1, 2017
Survey of diagnostic and treatment practices for multiple sclerosis in Europe
O Fernández, M Delvecchio, G Edan, et al.
European Journal of Neurology
|
January 23, 2018
Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management
O Fernández, M Delvecchio, G Edan, et al.
Neurology
|
August 18, 2006
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L Kappos, C H Polman, M S Freedman, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 123) with videos related to
Sort By:
Page
of 13
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 30, 2000
A quality network model for the daily care of multiple sclerosis
L D Blumhardt, B J Vermeij, M Amato, et al.
Neurology
|
May 20, 1999
Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group
D Brassat, C Azais-Vuillemin, J Yaouanq, et al.
Genes and Immunity
|
October 11, 2003
Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis
I Cournu-Rebeix, E Génin, G Lesca, et al.
Lancet (London, England)
|
May 30, 2001
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
G Comi, M Filippi, F Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 3, 2002
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis
R G Ghalie, E Mauch, G Edan, et al.
Journal of Neurology
|
April 12, 2006
Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?
D Drapier, S Drapier, P Sauleau, et al.
Journal of Neuroimmunology
|
May 15, 2010
Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response
J Kovalchin, J Krieger, M Genova, et al.
European Journal of Neurology
|
February 1, 2017
Survey of diagnostic and treatment practices for multiple sclerosis in Europe
O Fernández, M Delvecchio, G Edan, et al.
European Journal of Neurology
|
January 23, 2018
Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management
O Fernández, M Delvecchio, G Edan, et al.
Neurology
|
August 18, 2006
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L Kappos, C H Polman, M S Freedman, et al.
Page
of 13